Advertisement
UK markets open in 5 hours 57 minutes

  • NIKKEI 225

    37,310.42
    -769.28 (-2.02%)
     

  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     

  • CRUDE OIL

    82.60
    -0.13 (-0.16%)
     

  • GOLD FUTURES

    2,392.10
    -5.90 (-0.25%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    50,461.60
    +969.86 (+1.96%)
     

  • CMC Crypto 200

    1,304.59
    +419.05 (+46.96%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

AstraZeneca's immunotherapy enters U.S. approval process

Reuters - UK Focus

FRANKFURT, Dec (Shanghai: 600875.SS - news) 9 (Reuters) - AstraZeneca (NYSE: AZN - news) 's immunotherapy drug durvalumab, the British drugmaker's most important pipeline medicine, has been accepted for review by U.S. regulators against bladder cancer, potentially its first use.

The U.S. Food and Drug Administration also granted priority review status to the medicine, the company said, meaning trial data will be reviewed within six months instead of the usual 10. The drug boosts the immune system's ability to fight cancerous cells.

Durvalumab is being tested on its own and in combination with another immune system-boosting drug called tremelimumab in various cancers, including lung cancer, which represents the biggest market.

(Reporting by Ludwig Burger; Editing by Adrian Croft)